石四药集团(02005.HK)：盐酸氨溴索获国家药监局批准登记成为在上市制剂使用的原料药

Group 1 - The core point of the article is that Shijiazhuang Pharmaceutical Group (02005.HK) has received approval from the National Medical Products Administration of China for its active pharmaceutical ingredient, Ambroxol Hydrochloride, to be used in marketed formulations. Ambroxol Hydrochloride is an expectorant primarily used for treating respiratory diseases [1] - The company also announced that it has obtained production registration approvals for Calcium Gluconate and Sodium Chloride Injection (100ml:1g/0.8g) and Metronidazole Sodium Chloride Injection (100ml:0.5g/0.9g) [1]